You are here : Home > The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma

Publications CNRGH

The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma

Published on 2 October 2023
The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma
Description
 
Date de publication 
Auteurs
Hubert JN, Suybeng V, Vallee M, Delhomme TM, Maubec E, Boland A, Bacq D, Deleuze JF, Jouenne F, Brennan P, McKay JD, Avril MF, Bressac-de Paillerets B and Chanudet E
Revue
Année2,021
Département / Service
CNRGH
Laboratoire
LBanq, LBInf
Impact Factor6.64
InstitutJACOB
url DOI10.3390/cancers13092243

Go back to list